Sameer Hassamal

Sameer Hassamal, MD, FASAM, is a distinguished medical professional specializing in psychiatry and addiction medicine, currently serving as Principal Investigator at CVS Health and Tilda Research, overseeing phase I-III pharmaceutical trials. As Chief Executive Officer of The California Neuropsychiatric Institute, Sameer leads efforts in treating a wide array of mental health conditions, with a focus on evidence-based and newly approved treatments. Additional roles include serving as an Advisor at Guidepoint, Independent Medical Reviewer at Maximus, and CEO of Meera Therapeutics, where consulting services are provided to healthcare and biotechnology startups. Sameer also holds the position of Assistant Professor of Psychiatry at California University of Sciences and Medicine and has previous experience as Medical Director/Principal Investigator at PACIFIC CLINICAL RESEARCH MEDICAL GROUP. Sameer's educational background includes an MD from Virginia Commonwealth University and an MD in Addiction Psychiatry from UCLA, along with a BS in Biology from UC Irvine.